A Study of N9 Chemotherapy in Children With Neuroblastoma

Status Recruiting

Clinical Trial Summary

The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine (CDV).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04947501
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Brian Kushner, MD
Phone	1-833-MSK-KIDS
Email	kushnerb@MSKCC.ORG
Status	Recruiting
Phase	Early Phase 1
Start date	June 22, 2021
Completion date	June 22, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00492167` - Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma	Phase 1
Completed	`NCT04474678` - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")	N/A
Terminated	`NCT00801931` - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders	Phase 1/Phase 2
Active, not recruiting	`NCT03107988` - NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)	Phase 1
Recruiting	`NCT04253015` - A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
Terminated	`NCT00788125` - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT02933333` - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Phase 4
Recruiting	`NCT00588068` - Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Recruiting	`NCT04301843` - Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma	Phase 2
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting	`NCT04040088` - An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors	Early Phase 1
Recruiting	`NCT06057948` - A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma	Phase 2
Not yet recruiting	`NCT06335745` - PediCARE Health Equity Intervention in High-Risk Neuroblastoma	N/A
Recruiting	`NCT02559778` - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	Phase 2
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT02245997` - Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma	N/A
Not yet recruiting	`NCT01156350` - Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma	Phase 2
Active, not recruiting	`NCT01192555` - Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma	Phase 1/Phase 2
Completed	`NCT01222780` - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer	Phase 1